Trial Profile
Usefulness of Add-on Therapy of Pegylated Interferon alfa2a with Nucleoside/nucleotide Analog Treatment for Patients with Hepatitis B Virus Infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications Hepatitis B
- Focus Therapeutic Use
- 28 May 2021 Status changed from recruiting to active, no longer recruiting.
- 28 May 2018 New trial record